Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients

Página do item simplificado
dc.contributor.authorFerenci, Peter
dc.contributor.authorAires, Rodrigo
dc.contributor.authorBeavers, Kimberly L.
dc.contributor.authorCurescu, Manuela
dc.contributor.authorAbrao Ferreira, Paulo R. [UNIFESP]
dc.contributor.authorGschwantler, Michael
dc.contributor.authorIon, Stefan
dc.contributor.authorLarrey, Dominique
dc.contributor.authorMaticic, Mojca
dc.contributor.authorPuoti, Massimo
dc.contributor.authorSchuller, Janos
dc.contributor.authorTornai, Istvan
dc.contributor.authorTusnadi, Anna
dc.contributor.authorMessinger, Diethelm
dc.contributor.authorTatsch, Fernando
dc.contributor.authorHorban, Andrzej
dc.contributor.institutionMed Univ Vienna
dc.contributor.institutionGoias Fed Univ Clin Hosp
dc.contributor.institutionAsheville Gastroenterol Associates
dc.contributor.institutionUniv Med & Farm Timisoara
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionWilhelminenspital Stadt Wien
dc.contributor.institutionCent Mil Hosp
dc.contributor.institutionSt Eloi Hosp
dc.contributor.institutionUniv Med Ctr
dc.contributor.institutionSC Malattie Infett AO Osped Niguarda Ca Granda
dc.contributor.institutionSzent Laszlo Hosp
dc.contributor.institutionUniv Debrecen
dc.contributor.institutionHetenyi Geza Hosp
dc.contributor.institutionIST GmbH
dc.contributor.institutionF Hoffmann La Roche Ltd
dc.contributor.institutionMed Univ Warsaw
dc.contributor.institutionHosp Infect Dis
dc.date.accessioned2016-01-24T14:35:02Z
dc.date.available2016-01-24T14:35:02Z
dc.date.issued2014-01-01
dc.description.abstractAdvanced liver fibrosis is a negative predictor of virologic response in genotype 1 chronic hepatitis C (CHC) patients. Biopsy, however, is invasive, costly, and carries some risk of complications.Using data from the prospective, international cohort study PROPHESYS, we assessed two alternative noninvasive measures of fibrosis, the FIB-4 and AST-to-platelet ratio index (APRI), to predict virologic response in CHC patients.CHC genotype 1, monoinfected, treatment-naive patients prescribed peginterferon alfa-2a (40 KD)/ribavirin in accordance with country-specific legal and regulatory requirements and who had baseline METAVIR, FIB-4, and APRI scores (N = 1,592) were included in this analysis. Patients were stratified according to the baseline METAVIR, FIB-4, or APRI score to assess virologic response [hepatitis C virus (HCV) RNA < 50 IU/mL] by week 4 of treatment (rapid virologic response) and 24 weeks after untreated follow-up ]sustained virologic response (SVR)]. Baseline predictors of SVR were explored by multiple logistic regression, and the strength of the association between each fibrosis measure and SVR was evaluated. Both FIB-4 and APRI scores increased with increasing levels of biopsy-assessed fibrosis. the association between FIB-4 and SVR (p < 0.1 x 10(-30)) was stronger than that between METAVIR (p = 3.86 x 10(-13)) or APRI (p = 5.48 x 10(-6)) and SVR. Baseline factors significantly associated with SVR included male gender, lower HCV RNA, lower FIB-4 score, no steatosis, and higher alanine aminotransferase ratio.The FIB-4 index provides a valuable, noninvasive measure of fibrosis and can be used to predict virologic response in patients treated with peginterferon alfa-2a (40 KD)/ribavirin.en
dc.description.affiliationMed Univ Vienna, A-1090 Vienna, Austria
dc.description.affiliationGoias Fed Univ Clin Hosp, Goiania, Go, Brazil
dc.description.affiliationAsheville Gastroenterol Associates, Asheville, NC USA
dc.description.affiliationUniv Med & Farm Timisoara, Timisoara, Romania
dc.description.affiliationUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.affiliationWilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria
dc.description.affiliationCent Mil Hosp, Bucharest, Romania
dc.description.affiliationSt Eloi Hosp, Liver Unit, Montpellier, France
dc.description.affiliationUniv Med Ctr, Ljubljana, Slovenia
dc.description.affiliationSC Malattie Infett AO Osped Niguarda Ca Granda, Milan, Italy
dc.description.affiliationSzent Laszlo Hosp, Budapest, Hungary
dc.description.affiliationUniv Debrecen, Dept Internal Med 2, H-4012 Debrecen, Hungary
dc.description.affiliationHetenyi Geza Hosp, Infectol Dept, Szolnok, Hungary
dc.description.affiliationIST GmbH, Mannheim, Germany
dc.description.affiliationF Hoffmann La Roche Ltd, Basel, Switzerland
dc.description.affiliationMed Univ Warsaw, Warsaw, Poland
dc.description.affiliationHosp Infect Dis, Warsaw, Poland
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipF. Hoffmann-La Roche Ltd., Basel, Switzerland
dc.format.extent83-93
dc.identifierhttp://dx.doi.org/10.1007/s12072-013-9484-6
dc.identifier.citationHepatology International. New York: Springer, v. 8, n. 1, p. 83-93, 2014.
dc.identifier.doi10.1007/s12072-013-9484-6
dc.identifier.issn1936-0533
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/37232
dc.identifier.wosWOS:000330808600011
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofHepatology International
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectPeginterferon alfa-2aen
dc.subjectNoninvasive fibrosis measureen
dc.subjectFIB-4en
dc.subjectAPRIen
dc.subjectMETAVIRen
dc.titlePredictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patientsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos